Ralph Weichselbaum to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Ralph Weichselbaum has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.348
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.102
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.085
-
An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
Score: 0.065
-
More on cetuximab in head and neck cancer. N Engl J Med. 2007 Nov 22; 357(21):2201-2; author reply 2202-3.
Score: 0.042
-
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
Score: 0.031
-
Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
Score: 0.012
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.011